| Drug ID: | Drug47 |
|---|---|
| Drug Name: | Calcium carbonate |
| CID: | 10112 |
| DrugBank ID: | DB06724 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT04276649 |
| Molecular Formula: | CCaO3 |
| Molecular Weight: | 100.09 g/mol |
| Isomeric SMILES: | C(=O)([O-])[O-].[Ca+2] |
| Synonyms: | CALCIUM CARBONATE; 471-34-1; Aragonite; Calcium carbonate (1:1); Calofort U; Caltrate; Calwhite; Hydrocarb; Microcarb; Micromya |
| Phase 0: | 3 |
| Phase 1: | 19 |
| Phase 2: | 25 |
| Phase 3: | 26 |
| Phase 4: | 27 |
| Description: | Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. Calcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt433 | 10112 | Calcium Carbonate | 5744 | PTHLH | Homo sapiens (human) | 16006300 | Calcium carbonate results in decreased expression of PTHLH protein |
| dt434 | 10112 | Calcium Carbonate | 632 | BGLAP | Homo sapiens (human) | 2027271 | Calcium carbonate results in decreased expression of BGLAP protein |
| dt435 | 10112 | Calcium Carbonate | 823 | CAPN1 | Homo sapiens (human) | 24412303 | Calcium carbonate analog results in increased activity of CAPN1 protein |
| dt436 | 10112 | Calcium Carbonate | 836 | CASP3 | Homo sapiens (human) | 24412303 | Calcium carbonate analog results in increased activity of CASP3 protein |
| dt437 | 10112 | Calcium Carbonate | 1649 | DDIT3 | Homo sapiens (human) | 24412303 | Calcium carbonate analog results in increased expression of DDIT3 |
| dt438 | 10112 | Calcium Carbonate | 2539 | G6PD | Carassius auratus (goldfish) | 16735067 | Calcium carbonate results in decreased activity of G6PD protein |
| dt439 | 10112 | Calcium Carbonate | 2936 | GSR | Carassius auratus (goldfish) | 16735067 | Calcium carbonate results in decreased activity of GSR protein |
| dt440 | 10112 | Calcium Carbonate | 5741 | PTH | Homo sapiens (human) | 8481062 | Calcium carbonate affects the expression of PTH protein |
| dt441 | 10112 | Calcium Carbonate | 5741 | PTH | Homo sapiens (human) | Calcium carbonate results in decreased expression of PTH protein | |
| dt442 | 10112 | Calcium Carbonate | 6647 | SOD1 | Carassius auratus (goldfish) | 16735067 | Calcium carbonate results in increased activity of SOD1 protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| CTRI/2017/11/010336 | A study to assess the efficacy of vitamin D supplementation in preventing disease relapse in patients with inflammatory bowel disease. | Not Available | Not Recruiting | KMC Hospital | Health Condition 1: null- Inflammatory bowel dise… | Intervention1: Supplementation of Oral Cholecalif… | Details |
| NCT02470663 | Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium: A Prospective Randomized Multicenter Trial | Not Available | Not recruiting | Sheba Medical Center | Inflammatory Bowel Disease | Dietary Supplement: DENSITYTM caplets (marketed a… | Details |
| NCT04276649 | A Retrospective Analysis: the Influence of Caltrate Supplement on the Effect of Mesalazine in Ulcerative Colitis | None | COMPLETED | Second Affiliated Hospital of Wenzhou Medical University | Ulcerative Colitis|Vitamin D Deficiency|Vitamin D… | DRUG: Caltrate | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
No related literature
You can run management commands to establish drug-literature associations